Structure and Chemical Inhibition of the Ret Tyrosine Kinase Domain.
From: Structural Biology Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, UK.
The Journal of biological chemistry
- Publish Date: Nov 2006
- ISSN: 0021-9258
- Volume: 281
- Issue: 44
- Pages: 33577-87
- Medium: Print
- Language: English
- Citation (JAMA): Knowles Phillip P, Murray-Rust Judith, Kjaer Svend, et al. Structure and Chemical Inhibition of the Ret Tyrosine Kinase Domain.. J. Biol. Chem. Nov 2006;281:33577-87
Abstract
The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands. Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B. We report here the biochemical characterization of the human RET tyrosine kinase domain and the structure determination of the non-phosphorylated and phosphorylated forms. Both structures adopt the same active kinase conformation competent to bind ATP and substrate and have a pre-organized activation loop conformation that is independent of phosphorylation status. In agreement with the structural data, enzyme kinetic data show that autophosphorylation produces only a modest increase in activity. Longer forms of RET containing the juxtamembrane domain and C-terminal tail exhibited similar kinetic behavior, implying that there is no cis-inhibitory mechanism within the RET intracellular domain. Our results suggest the existence of alternative inhibitory mechanisms, possibly in trans, for the autoregulation of RET kinase activity. We also present the structures of the RET tyrosine kinase domain bound to two inhibitors, the pyrazolopyrimidine PP1 and the clinically relevant 4-anilinoquinazoline ZD6474. These structures explain why certain multiple endocrine neoplasia 2-associated RET mutants found in patients are resistant to inhibition and form the basis for design of more effective inhibitors.
Mesh Headings (Keywords): Animals, Binding Sites, Cell Line, Crystallography, X-Ray, Dimerization, Kinetics, Ligands, Models, Molecular, Mutation, Protein Structure, Quaternary, Protein Structure, Tertiary, Proto-Oncogene Proteins c-ret, Recombinant Proteins, Spodoptera
Check for Full Text / PubMed Unique Identifier (PMID): 16928683
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.